Boston Scientific Corporation (BSX) is scheduled to report first-quarter 2024 results on Apr 24, before the opening bell.In the last reported quarter, the company’s earnings per share of 55 cents exceeded the Zacks Consensus Estimate by 7.8%. BSX’s bottom line beat estimates in each of the trailing four quarters. The company delivered a trailing four-quarter earnings surprise of 7.37%, on average.Factors at PlayWith U.S. hospitals expected to report an increase in procedure volumes through the months of 202 ...

Boston Scientific Corporation (BSX) has been struggling due to unfavorable currency movement and macroeconomic woes. Strong competitors in the large medical device market also pose a tough challenge for Boston Scientific. The stock carries a Zacks Rank #4 (Sell) currently.The industry-wide trend of challenging macroeconomic conditions in the form of inflation, disruptions in economic activity, global supply chains and labor markets, volatile financial market dynamics and significant volatility in price and ...

波士顿科学公司新技术介绍 - 波士顿科学公司启动了NAVIGATE-PF研究，旨在评估FARAVIEW™软件模块在可视化和跟踪FARAWAVE™ Nav脉冲场消融导管治疗阵发性和持续性心房颤动患者时的效果[1] - FARAVIEW技术和FARAWAVE Nav导管通过与心脏电图系统集成，扩展了FARAPULSE™ PFA系统的功能[1] - FARAWAVE Nav PFA导管增加了磁导航功能，使得在同一设备内进行详细的心脏电图绘制和PFA治疗成为可能[3] NAVIGATE-PF研究详情 - 在NAVIGATE-PF研究中，将有大约30名欧洲中心的患有阵发性或持续性AF的患者参与，所有患者都将在手术过程中进行心脏电图绘制[4] 未来展望 - 波士顿科学公司预计FARAWAVE NAV PFA导管和FARAVIEW软件模块将在2024年下半年获得美国监管批准[5]

公司业绩 - 波士顿科学公司将于2024年4月24日举行财务业绩和业务亮点的电话会议[1] - 公司将在4月24日电话会议之前发布第一季度财务业绩的新闻稿[1] 会议信息 - 会议将由主席兼首席执行官Mike Mahoney和首席财务官Dan Brennan主持[1] - 可以在htts://investors.bostonscientific.com上观看现场网络直播和重播[2] 公司业务 - 波士顿科学公司通过创新的医疗技术改善全球患者的健康[3] - 公司提供一系列高性能解决方案，帮助医生诊断和治疗复杂的心血管、呼吸、消化、肿瘤、神经和泌尿系统疾病和病况[3] - 了解更多信息，请访问www.bostonscientific.com[3]

Boston Scientific (BSX) is gaining traction in the emerging markets. New regulatory approvals and accretive acquisitions bode well for its long-term growth. Yet, an unfavorable currency movement and macroeconomic concerns are major dampeners. The stock carries a Zacks Rank #3 (Hold) at present.BSX successfully continues with its expansion of operations across different geographies outside the United States. In 2022, 40% of the company’s consolidated revenues came from international regions.The company is al ...

Boston Scientific Corporation (BSX) achieved a milestone with the recent FDA approval for its AGENT Drug-Coated Balloon (DCB). This marks the first drug-coated coronary balloon available in the United States.This approval signals a key advancement in the treatment landscape for coronary in-stent restenosis (ISR), a challenging condition characterized by the narrowing of stented vessels due to plaque or scar tissue formation. With this, Boston Scientific is expected to broaden its Interventional Cardiology ( ...

Zacks Premium - Zacks Premium提供了多种方式帮助投资者充分利用股市和投资，包括Zacks Rank和Zacks Industry Rank的每日更新，Zacks 1 Rank List，Equity Research报告和Premium股票筛选[1] Zacks Style Scores - Zacks Style Scores是一套独特的指导原则，根据三种流行的投资类型对股票进行评级，帮助投资者选择在未来30天内击败市场机会最高的证券[3] - Style Scores分为四个类别：价值评分、成长评分、动量评分和VGM评分，分别评估股票的价值、增长、动量和综合表现[5][6][7][8] Zacks Rank - Zacks Rank利用盈利预期修订的力量帮助投资者创建成功的投资组合，1 (Strong Buy)股票自1988年以来的平均年回报率超过25.41%，是标普500指数表现的两倍以上[9][10] 投资策略 - 为了最大化回报，投资者应选择具有Zacks Rank 1或2且Style Scores为A或B的股票，确保股票的盈利预期趋势向上[12][13] - 举例说明，即使股票具有A和B的Style Scores，但如果评级为4 (Sell)或5 (Strong Sell)，其盈利预期仍呈下降趋势，股价可能会下跌[14] Boston Scientific (BSX) - Boston Scientific (BSX)是一家总部位于马萨诸塞州南提克，成立于1979年的医疗器械和产品制造公司，目前在Zacks Rank上为3 (Hold)，VGM Score为B[15] - BSX具有良好的动量和VGM Style Scores，分析师对其2024财年盈利预期持续上调，应该被投资者列入关注名单[17]

First coronary drug-coated balloon in U.S. provides safe, effective alternative to treat coronary in-stent restenosis and reduce risk of reoccurrence MARLBOROUGH, Mass., March 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR is the obstruction or narrowing of a ...

公司债券发行 - 波士顿科学公司宣布其全资金融子公司完成了价值7.5亿欧元的3.375%到期于2029年和12.5亿欧元的3.500%到期于2032年的债券发行[1] - 公司计划利用债券发行的净收益，商业票据计划的借款和现金，用于收购Axonics, Inc.的购买价格，并支付相关费用和支出，以及偿还到期的3.450%到期于2024年的优先债券的本金和支付应计未付利息，以及用于一般企业用途[2] 公司业务 - 波士顿科学通过创新的医疗技术改善全球患者的健康，提供一系列高性能解决方案，帮助医生诊断和治疗复杂的心血管、呼吸、消化、肿瘤、神经和泌尿系统疾病和病况[3]

Have you been paying attention to shares of Boston Scientific (BSX) ? Shares have been on the move with the stock up 8.7% over the past month. The stock hit a new 52-week high of $67.32 in the previous session. Boston Scientific has gained 15.3% since the start of the year compared to the 7.8% move for the Zacks Medical sector and the 6.5% return for the Zacks Medical - Products industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our ea ...